SI2528627T1 - Radioimunski konjugati in njihova uporaba - Google Patents

Radioimunski konjugati in njihova uporaba

Info

Publication number
SI2528627T1
SI2528627T1 SI201130157T SI201130157T SI2528627T1 SI 2528627 T1 SI2528627 T1 SI 2528627T1 SI 201130157 T SI201130157 T SI 201130157T SI 201130157 T SI201130157 T SI 201130157T SI 2528627 T1 SI2528627 T1 SI 2528627T1
Authority
SI
Slovenia
Prior art keywords
radioimmunoconjugates
Prior art date
Application number
SI201130157T
Other languages
English (en)
Slovenian (sl)
Inventor
Roy H. Larsen
Jostein Dahle
Oyvind S. Bruland
Original Assignee
Nordic Nanovector As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector As filed Critical Nordic Nanovector As
Publication of SI2528627T1 publication Critical patent/SI2528627T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201130157T 2010-01-29 2011-01-28 Radioimunski konjugati in njihova uporaba SI2528627T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof
EP11700972.0A EP2528627B1 (en) 2010-01-29 2011-01-28 Radioimmunoconjugates and uses thereof

Publications (1)

Publication Number Publication Date
SI2528627T1 true SI2528627T1 (sl) 2014-08-29

Family

ID=44319900

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130157T SI2528627T1 (sl) 2010-01-29 2011-01-28 Radioimunski konjugati in njihova uporaba

Country Status (25)

Country Link
US (2) US8628749B2 (enExample)
EP (2) EP2528627B1 (enExample)
JP (2) JP5646652B2 (enExample)
KR (2) KR101758409B1 (enExample)
CN (2) CN104338154B (enExample)
AU (1) AU2011209441B2 (enExample)
BR (1) BR112012018843B8 (enExample)
CA (1) CA2786655C (enExample)
DK (2) DK2705857T3 (enExample)
ES (2) ES2592402T3 (enExample)
HR (1) HRP20140538T1 (enExample)
IL (2) IL221091A (enExample)
MX (2) MX2012008695A (enExample)
NO (1) NO331080B1 (enExample)
NZ (1) NZ601055A (enExample)
PH (2) PH12012501516A1 (enExample)
PL (1) PL2528627T3 (enExample)
PT (1) PT2528627E (enExample)
RS (1) RS53346B (enExample)
RU (2) RU2560587C9 (enExample)
SG (1) SG182685A1 (enExample)
SI (1) SI2528627T1 (enExample)
UA (1) UA108631C2 (enExample)
WO (1) WO2011092295A2 (enExample)
ZA (1) ZA201205007B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272364B1 (en) * 2011-12-13 2020-07-29 Nordic Nanovector ASA Chimeric therapeutic anti-cd37 antibodie hh1
RU2014140119A (ru) * 2012-03-30 2016-05-27 Иммьюноджен, Инк. Способы повышения эффективности терапии на основе cd37
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
HK1250646A1 (zh) * 2015-04-07 2019-01-11 Memorial Sloan Kettering Cancer Center 纳米粒子免疫偶联物
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
SG11201901672RA (en) * 2016-09-16 2019-03-28 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
MX2023011031A (es) * 2021-03-19 2023-12-14 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo especificos de linfocitos b.
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
CA2509103A1 (en) * 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP4874090B2 (ja) * 2003-01-31 2012-02-08 イミューノメディクス、インコーポレイテッド 治療薬および診断薬を投与するための方法および組成物
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
AU2006272555B2 (en) * 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
EP2705857A2 (en) 2014-03-12
CA2786655C (en) 2016-12-13
RS53346B (sr) 2014-10-31
KR101758409B1 (ko) 2017-07-14
AU2011209441A1 (en) 2012-07-19
US20120301396A1 (en) 2012-11-29
AU2011209441B2 (en) 2016-03-03
WO2011092295A2 (en) 2011-08-04
UA108631C2 (xx) 2015-05-25
EP2528627B1 (en) 2014-03-19
IL237507A0 (en) 2015-04-30
US20140147384A1 (en) 2014-05-29
CN104338154B (zh) 2017-09-22
CN102762230A (zh) 2012-10-31
PH12017501038B1 (en) 2019-02-22
IL221091A0 (en) 2012-09-24
KR101893720B1 (ko) 2018-08-30
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
NO331080B1 (no) 2011-09-26
DK2528627T3 (da) 2014-05-12
NO20100143A1 (no) 2011-08-01
DK2705857T3 (en) 2016-08-29
RU2560587C9 (ru) 2015-11-27
BR112012018843A8 (pt) 2017-12-19
BR112012018843A2 (pt) 2017-10-17
ES2592402T3 (es) 2016-11-30
EP2705857B1 (en) 2016-06-22
JP2015057415A (ja) 2015-03-26
KR20130028051A (ko) 2013-03-18
EP2528627A2 (en) 2012-12-05
HK1195736A1 (en) 2014-11-21
ZA201205007B (en) 2013-09-25
MX342539B (es) 2016-10-04
US9358309B2 (en) 2016-06-07
CA2786655A1 (en) 2011-08-04
PH12017501038A1 (en) 2017-12-11
BR112012018843B8 (pt) 2020-12-22
RU2012135430A (ru) 2014-03-10
HK1179157A1 (en) 2013-09-27
PT2528627E (pt) 2014-06-12
PL2528627T3 (pl) 2014-08-29
CN104338154A (zh) 2015-02-11
JP5855209B2 (ja) 2016-02-09
BR112012018843B1 (pt) 2020-09-24
PH12012501516A1 (en) 2024-04-03
KR20170084349A (ko) 2017-07-19
IL221091A (en) 2015-03-31
ES2469140T3 (es) 2014-06-17
CN102762230B (zh) 2014-08-13
HRP20140538T1 (hr) 2014-07-18
WO2011092295A3 (en) 2011-11-24
MX2012008695A (es) 2012-11-23
JP5646652B2 (ja) 2014-12-24
JP2013518086A (ja) 2013-05-20
US8628749B2 (en) 2014-01-14
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
EP2705857A3 (en) 2014-07-30

Similar Documents

Publication Publication Date Title
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
IL221091A (en) Radioimmunoconjugates and their uses
PL2539326T3 (pl) Połączone bis-arylem arylotriazolony i ich zastosowanie
IL226904A (en) Inganol-3-acetylates iii and Inganol-3-carbamates
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
ZA201209259B (en) Uses and compositions
ZA201208173B (en) Peptices and their use
SG10201508958WA (en) Heterocyclic Compounds And Uses Thereof
PL2531518T3 (pl) Związki oligopeptydowe i ich zastosowania
IL220812A0 (en) Compounds and methods
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
ZA201303773B (en) Compounds and their use
SI2552440T1 (sl) Nove kombinacije in uporaba
GB201014319D0 (en) Compounds and uses thereof
GB201020268D0 (en) Composition and uses
GB201017822D0 (en) Compounds and their use
GB201020848D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201002337D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use
GB201018028D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201019291D0 (en) Compositions and uses